Sacubitril/valsartan vs enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study: sacubitril/valsartan and enalapril on peak VO 2 in patients with heart failure wi
American Heart Journal May 28, 2021
dos Santos MR, de Nazaré Nunes Alves MJ, Jordao CP, et al. - The present study was conducted to correlate sacubitril/valsartan versus enalapril in patients with heart failure with reduced ejection fraction (HFrEF) based on peak oxygen consumption (VO 2 ) and 6-minute walk test (6-MWT). Researchers enrolled a total of 52 individuals with HFrEF with a left ventricular ejection fraction < 40% to receive either sacubitril/valsartan (target dose of 400 mg daily) or enalapril (target dose of 40 mg daily). Cardiopulmonary exercise testing was used to measure peak VO 2. They further conducted a six-minute walk test. The results indicate that sacubitril/valsartan did not substantially improve peak VO 2 or 6-MWT after 12 or 24 weeks in comparison with enalapril in participants with HFrEF.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries